{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:30Z","timestamp":1787020110050,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-025-00711-w","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:42:26Z","timestamp":1744764146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic"],"prefix":"10.1186","volume":"26","author":[{"given":"Sakiko","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Sueoka-Aragane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintaro","family":"Sogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Furuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriyasu","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Noshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Shimanoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: Past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324. https:\/\/doi.org\/10.1016\/j.cancergen.2024.06.002.","journal-title":"Cancer Genet"},{"issue":"1","key":"711_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","volume":"8","author":"M Chavez-MacGregor","year":"2022","unstructured":"Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol. 2022;8(1):69\u201378. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5148.","journal-title":"JAMA Oncol"},{"issue":"8","key":"711_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.31617","volume":"6","author":"SM Hosseini-Moghaddam","year":"2023","unstructured":"Hosseini-Moghaddam SM, Shepherd FA, Swayze S, Kwong JC, Chan KKW. SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without Cancer. JAMA Netw Open. 2023;6(8): e2331617. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31617.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"711_CR4","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/s1470-2045(24)00107-4","volume":"25","author":"L Turtle","year":"2024","unstructured":"Turtle L, Elliot S, Drake TM, Thorpe M, Khoury EG, Greenhalf W, Hardwick HE, Leeming G, Law A, Oosthuyzen W, Pius R, Shaw CA, Baillie JK, Openshaw PJM, Docherty AB, Semple MG, Harrison EM, Palmieri C. Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study. Lancet Oncol. 2024;25(5):636\u201348. https:\/\/doi.org\/10.1016\/s1470-2045(24)00107-4.","journal-title":"Lancet Oncol"},{"issue":"12","key":"711_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1001\/jamaoncol.2020.5403","volume":"6","author":"HE Hartman","year":"2020","unstructured":"Hartman HE, Sun Y, Devasia TP, Chase EC, Jairath NK, Dess RT, Jackson WC, Morris E, Li P, Hochstedler KA, Abbott MR, Kidwell KM, Walter V, Wang M, Wang X, Zaorsky NG, Schipper MJ, Spratt DE. Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic. JAMA Oncol. 2020;6(12):1881\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5403.","journal-title":"JAMA Oncol"},{"issue":"3","key":"711_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2022.6815","volume":"9","author":"IY Gong","year":"2023","unstructured":"Gong IY, Vijenthira A, Powis M, Calzavara A, Patrikar A, Sutradhar R, Hicks LK, Wilton D, Singh S, Krzyzanowska MK, Cheung MC. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer. JAMA Oncol. 2023;9(3):386\u201394. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6815.","journal-title":"JAMA Oncol"},{"issue":"8","key":"711_CR7","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41591-021-01387-6","volume":"27","author":"L Au","year":"2021","unstructured":"Au L, Fendler A, Shepherd STC, Rzeniewicz K, Cerrone M, Byrne F, Carlyle E, Edmonds K, Del Rosario L, Shon J, Haynes WA, Ward B, Shum B, Gordon W, Gerard CL, Xie W, Joharatnam-Hogan N, Young K, Pickering L, Furness AJS, Larkin J, Harvey R, Kassiotis G, Gandhi S, Swanton C, Fribbens C, Wilkinson KA, Wilkinson RJ, Lau DK, Banerjee S, Starling N, Chau I, Turajlic S. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nat Med. 2021;27(8):1362\u20136. https:\/\/doi.org\/10.1038\/s41591-021-01387-6.","journal-title":"Nat Med"},{"issue":"1","key":"711_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-021-01618-0","volume":"126","author":"P Brest","year":"2022","unstructured":"Brest P, Mograbi B, Hofman P, Milano G. COVID-19 vaccination and cancer immunotherapy: should they stick together? Br J Cancer. 2022;126(1):1\u20133. https:\/\/doi.org\/10.1038\/s41416-021-01618-0.","journal-title":"Br J Cancer"},{"issue":"36","key":"711_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/jco.21.01440.","journal-title":"J Clin Oncol"},{"issue":"6","key":"711_CR10","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"711_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"key":"711_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363: k4226. https:\/\/doi.org\/10.1136\/bmj.k4226.","journal-title":"BMJ"},{"issue":"9","key":"711_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380. https:\/\/doi.org\/10.1038\/s41571-019-0218-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"711_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M, Navani V. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Netw Open. 2024;7(1): e2352302. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52302.","journal-title":"JAMA Netw Open"},{"issue":"34","key":"711_CR15","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/jco.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebb\u00e9 C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017;35(34):3815\u201322. https:\/\/doi.org\/10.1200\/jco.2016.72.1167.","journal-title":"J Clin Oncol"},{"issue":"11","key":"711_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/s1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fern\u00e1ndez MG, Li J, Lowery MA, \u00c7il T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/s1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"711_CR17","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv264\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdy162.","journal-title":"Ann Oncol"},{"key":"711_CR18","doi-asserted-by":"publisher","unstructured":"Jim HSL, Knoop H, Dicker AP (2021) Immune Checkpoint Inhibitor Therapy Toxicities. In: Jama, vol 326. vol 1. United States, p 87. https:\/\/doi.org\/10.1001\/jama.2021.6030","DOI":"10.1001\/jama.2021.6030"},{"issue":"2","key":"711_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100787","volume":"8","author":"V Amoroso","year":"2023","unstructured":"Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F, Berruti A. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open. 2023;8(2): 100787. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100787.","journal-title":"ESMO Open"},{"key":"711_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, Dumas E, Bihan K, Lebrun-Vignes B, Moslehi J, Spano JP, Laas E, Hotton J, Reyal F, Hamy AS, Salem JE. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024;70: 102536. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102536.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"711_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00262-024-03803-5","volume":"73","author":"AL Gradone","year":"2024","unstructured":"Gradone AL, Ma VT, Vasbinder A, Fecher LA, Yentz S, Hayek SS, Lao CD. Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era. Cancer Immunol Immunother. 2024;73(12):259. https:\/\/doi.org\/10.1007\/s00262-024-03803-5.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"711_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-024-03858-4","volume":"74","author":"Z Li","year":"2024","unstructured":"Li Z, Zhou Z, Zhang N, Tian B, Chen X, Zhao H, Wang H. Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database. Cancer Immunol Immunother. 2024;74(1):25. https:\/\/doi.org\/10.1007\/s00262-024-03858-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"711_CR23","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1007\/s00415-023-11667-5","volume":"270","author":"T Tezuka","year":"2023","unstructured":"Tezuka T, Okuzumi S, Nakashima C, Ide T, Imai S, Mitsuboshi S, Kuwahara Y, Takizawa T, Seki M, Minematsu N, Aragane N, Nakahara J, Hori S, Nakane S, Suzuki S. Dysautonomia associated with immune checkpoint inhibitors. J Neurol. 2023;270(7):3413\u201323. https:\/\/doi.org\/10.1007\/s00415-023-11667-5.","journal-title":"J Neurol"},{"key":"711_CR24","doi-asserted-by":"publisher","first-page":"1407894","DOI":"10.3389\/fphar.2024.1407894","volume":"15","author":"G Liu","year":"2024","unstructured":"Liu G, Zhang S, Mo Z, Huang T, Yu Q, Lu X, He P. Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database. Front Pharmacol. 2024;15:1407894. https:\/\/doi.org\/10.3389\/fphar.2024.1407894.","journal-title":"Front Pharmacol"},{"key":"711_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. https:\/\/doi.org\/10.1186\/s12916-015-0455-8.","journal-title":"BMC Med"},{"issue":"10","key":"711_CR26","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377\u201385. https:\/\/doi.org\/10.1093\/annonc\/mdx286.","journal-title":"Ann Oncol"},{"issue":"4","key":"711_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/onco.13654","volume":"26","author":"A Zambelli","year":"2021","unstructured":"Zambelli A, Chiudinelli L, Fotia V, Negrini G, Bosetti T, Callegaro A, Di Croce A, Caremoli ER, Moro C, Milesi L, Poletti P, Tasca C, Mandal\u00e0 M, Merelli B, Mosconi S, Arnoldi E, Bettini A, Bonomi L, Messina C, Ghilardi L, Chirco A, Maracino M, Tondini C. Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic. Oncologist. 2021;26(4):341\u20137. https:\/\/doi.org\/10.1002\/onco.13654.","journal-title":"Oncologist"},{"issue":"2","key":"711_CR28","doi-asserted-by":"publisher","first-page":"e0262784","DOI":"10.1371\/journal.pone.0262784","volume":"17","author":"A Candoni","year":"2022","unstructured":"Candoni A, Petruzzellis G, Sperotto A, Andreotti V, Giavarra M, Corvaja C, Minisini A, Comuzzi C, Tascini C, Fanin R, Fasola G. Detection of SARS-CoV-2 infection prevalence in 860 cancer patients with a combined screening procedure including triage, molecular nasopharyngeal swabs and rapid serological test. A report from the first epidemic wave. PLoS One. 2022;17(2):e0262784. https:\/\/doi.org\/10.1371\/journal.pone.0262784.","journal-title":"PLoS One."},{"issue":"1","key":"711_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/jamaoncol.2021.6199","volume":"8","author":"DJ Pinato","year":"2022","unstructured":"Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Bower M, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Segu\u00ed E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Ottaviani D, Li\u00f1an R, Rossi S, Carmona-Garc\u00eda MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Queirolo P, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqu\u00e9 Lloveras A, Newsom-Davis T, Sharkey R, Rold\u00e1n E, Reyes R, Zoratto F, Earnshaw I, Ferrante D, Marco-Hern\u00e1ndez J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Berardi R, Giusti R, Mazzoni F, Guida A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, Van Hemelrijck M, Diamantis N, Gennari A, Cortellini A. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. JAMA Oncol. 2022;8(1):114\u201322. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6199.","journal-title":"JAMA Oncol"},{"issue":"6","key":"711_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","volume":"32","author":"P Grivas","year":"2021","unstructured":"Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32(6):787\u2013800. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.024.","journal-title":"Ann Oncol"},{"issue":"12","key":"711_CR31","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/s1470-2045(21)00574-x","volume":"22","author":"SF Oosting","year":"2021","unstructured":"Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, Westphal TT, Bhattacharya A, van der Heiden M, Rimmelzwaan GF, Kvistborg P, Blank CU, Koopmans MPG, Huckriede ALW, van Els C, Rots NY, van Baarle D, Haanen J, de Vries EGE. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22(12):1681\u201391. https:\/\/doi.org\/10.1016\/s1470-2045(21)00574-x.","journal-title":"Lancet Oncol"},{"issue":"1","key":"711_CR32","doi-asserted-by":"publisher","first-page":"2207438","DOI":"10.1080\/21645515.2023.2207438","volume":"19","author":"D Gilbert","year":"2023","unstructured":"Gilbert D, Hu J, Medina T, Kessler ER, Lam ET. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors. Hum Vaccin Immunother. 2023;19(1):2207438. https:\/\/doi.org\/10.1080\/21645515.2023.2207438.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"711_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.6004\/jnccn.2022.7048","volume":"20","author":"AJ Widman","year":"2022","unstructured":"Widman AJ, Cohen B, Park V, McClure T, Wolchok J, Kamboj M. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade. J Natl Compr Canc Netw. 2022;20(10):1134\u20138. https:\/\/doi.org\/10.6004\/jnccn.2022.7048.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"711_CR34","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00262-021-03133-w","volume":"71","author":"SB Strobel","year":"2022","unstructured":"Strobel SB, Machiraju D, K\u00e4lber KA, Hassel JC. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. Cancer Immunol Immunother. 2022;71(8):2051\u20136. https:\/\/doi.org\/10.1007\/s00262-021-03133-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"711_CR35","doi-asserted-by":"publisher","first-page":"e006246","DOI":"10.1136\/jitc-2022-006246","volume":"11","author":"JI Ruiz","year":"2023","unstructured":"Ruiz JI, Lopez-Olivo MA, Geng Y, Suarez-Almazor ME. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother Cancer. 2023;11(2):e006246. https:\/\/doi.org\/10.1136\/jitc-2022-006246.","journal-title":"J Immunother Cancer."},{"issue":"5","key":"711_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/s1470-2045(21)00155-8","volume":"22","author":"B Waissengrin","year":"2021","unstructured":"Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021;22(5):581\u20133. https:\/\/doi.org\/10.1016\/s1470-2045(21)00155-8.","journal-title":"Lancet Oncol"},{"key":"711_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108399","volume":"245","author":"SV Retnakumar","year":"2023","unstructured":"Retnakumar SV, Chauvin C, Bayry J. The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases. Pharmacol Ther. 2023;245: 108399. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108399.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"711_CR38","doi-asserted-by":"publisher","first-page":"e008151","DOI":"10.1136\/jitc-2023-008151","volume":"12","author":"RA Watson","year":"2024","unstructured":"Watson RA, Ye W, Taylor CA, Jungkurth E, Cooper R, Tong O, James T, Shine B, Hofer M, Jenkins D, Pell R, Ieremia E, Jones S, Maldonado-Perez D, Roberts ISD, Coupe N, Middleton MR, Payne MJ, Fairfax BP. Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination. J Immunother Cancer. 2024;12(4):e008151. https:\/\/doi.org\/10.1136\/jitc-2023-008151.","journal-title":"J Immunother Cancer"},{"key":"711_CR39","doi-asserted-by":"publisher","unstructured":"Sumi T, Koshino Y, Michimata H, Nagayama D, Watanabe H, Yamada Y, Chiba H (2022) Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report. In: Transl Lung Cancer Res. 2022;11(9). Translational Lung Cancer Research. All rights reserved., China, pp 1973\u20131976. https:\/\/doi.org\/10.21037\/tlcr-22-388","DOI":"10.21037\/tlcr-22-388"},{"issue":"12","key":"711_CR40","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2217\/imt-2021-0342","volume":"14","author":"A Lasagna","year":"2022","unstructured":"Lasagna A, Lenti MV, Cassaniti I, Sacchi P. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy. 2022;14(12):915\u201325. https:\/\/doi.org\/10.2217\/imt-2021-0342.","journal-title":"Immunotherapy"},{"key":"711_CR41","doi-asserted-by":"publisher","unstructured":"Makiguchi T, Fukushima T, Tanaka H, Taima K, Takayasu S, Tasaka S (2022) Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report. In: Thorac Cancer, vol 13. vol 8. \u00a9 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd., Singapore, pp 1220\u20131223. https:\/\/doi.org\/10.1111\/1759-7714.14352","DOI":"10.1111\/1759-7714.14352"},{"key":"711_CR42","doi-asserted-by":"publisher","unstructured":"Mieczkowska K, Kaubisch A, McLellan BN (2021) Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. In: Dermatol Ther, vol 34. vol 5. United States, p e15055. https:\/\/doi.org\/10.1111\/dth.15055","DOI":"10.1111\/dth.15055"},{"issue":"23","key":"711_CR43","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","volume":"385","author":"G Witberg","year":"2021","unstructured":"Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. 2021;385(23):2132\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2110737.","journal-title":"N Engl J Med"},{"issue":"1","key":"711_CR44","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1186\/s12889-024-20297-z","volume":"24","author":"R Karam","year":"2024","unstructured":"Karam R, Iskandar K, Watfa M, Zeitoun A. Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database. BMC Public Health. 2024;24(1):2905. https:\/\/doi.org\/10.1186\/s12889-024-20297-z.","journal-title":"BMC Public Health"},{"issue":"19","key":"711_CR45","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1182\/bloodadvances.2023010105","volume":"7","author":"S Ochoa","year":"2023","unstructured":"Ochoa S, Abers MS, Rosen LB, Rump A, Howe K, Lieberman JA, Wright BL, Suez D, Krausz M, Grimbacher B, Lionakis MS, Uzel G. Management and outcome of COVID-19 in CTLA-4 insufficiency. Blood Adv. 2023;7(19):5743\u201351. https:\/\/doi.org\/10.1182\/bloodadvances.2023010105.","journal-title":"Blood Adv"},{"issue":"3","key":"711_CR46","doi-asserted-by":"publisher","first-page":"bbac129","DOI":"10.1093\/bib\/bbac129","volume":"23","author":"A Lin","year":"2022","unstructured":"Lin A, Qi C, Wei T, Li M, Cheng Q, Liu Z, Luo P, Zhang J. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Brief Bioinform. 2022;23(3):bbac129. https:\/\/doi.org\/10.1093\/bib\/bbac129.","journal-title":"Brief Bioinform."},{"key":"711_CR47","doi-asserted-by":"publisher","first-page":"1486652","DOI":"10.3389\/fimmu.2024.1486652","volume":"15","author":"Z Liu","year":"2024","unstructured":"Liu Z, Han L, Ji X, Wang X, Jian J, Zhai Y, Xu Y, Wang F, Ning F. Multi-omics analysis and experiments uncover the function of cancer stemness in ovarian cancer and establish a machine learning-based model for predicting immunotherapy responses. Front Immunol. 2024;15:1486652. https:\/\/doi.org\/10.3389\/fimmu.2024.1486652.","journal-title":"Front Immunol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00711-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00711-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00711-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:42:27Z","timestamp":1744764147000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00711-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00711-w","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Clinical Research Ethics Review Committee of Saga University Hospital (Saga University Clinical Research Review Board; Approval No.: 2023-12-02), and conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki. The need for informed consent was waived owing to the retrospective nature of the study. The official website of our institution was used to allow patients to opt out from participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}